

1 Supplemental material for :

2

3

4 **Avidity and variable domain spacing strongly influence the therapeutic potency of**

5 **bispecific antibodies against Crimean-Congo hemorrhagic fever virus**

6

7 Albert Wang,^{a^} Stephanie R. Monticelli,^{b,c*^} Ariel S. Wirchnianski,^a Dafna M. Abelson,^d

8 Ana I. Kuehne,^b Russell R. Bakken,^b Marissa Middlecamp,^d Michael Weingart,^d Olivia

9 Vergnolle,^{e*}, Zachary A. Bornholdt,^{d*} Crystal L. Moyer,^{d*} Jacob L. Berrigan,^a Brandyn R.

10 West,^{d*} J. Maximilian Fels,^{a*} Larry Zeitlin,^d Andrew S. Herbert,^{b§} Kartik Chandran,^{a§}

11 Chowdhury Raihan Bikash,^{e*#§} Jonathan R. Lai^{e#§}

12

13

DVD-Ig	Heavy chain linker	Light chain linker
DVD-121-801	ASTKGP	TVAAP
DVD-121-801 ^{GS}	GGGGSGGGGGSGGGG	GGSGGGGSGGGGS
DVD-121-801 ^{SVF}	ASTKGPSVFPLAP	TVAAPSVFIFPP
DVD-121-121	ASTKGP	TVAAP
DVD-121-121x	ASTKGP	TVAAP
DVD-121x-121	ASTKGP	TVAAP
DVD-121-F4	ASTKGP	TVAAP

1
2
3
4
5

Supplemental Table 1: Linkers of designed DVD-Ig molecules, related to Figure 1.

	Virus						
	tecVLP	CCHFV					
Antibody	IbAr 10200	IbAr 10200	Oman	Hoti	Turkey	Afg09	M18-China
ADI-36121	0.1082	0.0127	0.1746	0.1724	0.0829	0.0884	0.0106
ADI-37801	n/a	2.404	3.986	n/a	18.31	weak	2.799
ADI-37801 ^{C49}	n/a	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
121 + 801 cocktail	n.d.	0.0228	0.2287	0.2421	0.0875	0.1380	0.0181
DVD-121-801	0.0589	0.0030	0.0920	0.1015	0.0521	0.0807	0.0078
DVD-121-801 ^{C49}	0.0384	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.
DVD-121-801 ^{GS}	0.0387	0.0092	0.0978	0.0683	0.0529	0.0652	0.0086
DVD-121-801 ^{SVF}	0.0487	0.0058	0.0591	0.0738	0.0623	0.0564	0.0079
DVD-121-121	0.0421	0.0078	0.0652	0.0630	0.0278	0.0540	0.0043
DVD-121-121x	0.1471	0.0536	0.2751	0.2259	0.1530	0.2106	0.0227
DVD-121x-121	0.6778	0.0319	0.6810	2.293	0.1402	0.7059	0.0266
DVD-121-F4	0.0630	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.


6
7
8
9

Supplemental Table 2: Relative IC₅₀ values (nM) of parental mAbs and DVD-121-801 bsAb variants, related to Figure 2.

10 IC₅₀ values were derived from neutralization curves fitted with a four-parameter non-linear regression (**Figures S1, S2**). ADI-37801 was non-neutralizing against tecVLPs (IbAr10200), CCHFV-Hoti, and weakly neutralizing against CCHFV-Afg09. Similarly, ADI-37801^{C49} was non-neutralizing against tecVLPs. Authentic virus neutralization assays for DVD-121-F4, ADI-37801^{C49}, and DVD-121-801^{C49} were not performed.

15
16 n.d. not determined.

17
18




1
2
3 **Supplemental Figure 1: TecVLP neutralization by parental mAbs and DVD-121-801**
4 **bsAb variants, related to Figure 2.**

5
6 **S1A-C** Neutralization plots (N= 3-10, n= 9-30) of parental mAbs and DVD-IgS (**S1A**),
7 DVD-121-801 linker variants (**S1B**), and bispecific 121 variants (**S1C**). Plots were fitted
8 with a four-parameter non-linear regression model. Infection levels were normalized
9 relative infected cells in the absence of antibody treatment. **S1D** Absolute IC₅₀ values of
10 the parental mAbs and DVD-IgS were compared by one-way ANOVA with Dunnett's T3
11 multiple comparisons test, following tests for normality (**S1E**) and homoscedasticity (not
12 shown).

13
14 *** p ≤ 0.001; * p ≤ 0.05; n.s. p > 0.05.

1




2

1 **Supplemental Figure 2:** Authentic CCHFV neutralization by parental mAbs and DVD-
2 121-801 bsAb variants, related to Figure 2.

3


4 **S2A-F** Neutralization plots (N= 3-5, n= 8-15) of parental mAbs and DVD-Igs, DVD-121-
5 801 linker variants, and bispecific 121 variants against CCHFV strains IbAr10200 (**S2A**),
6 Oman (**S2B**), Hoti (**S2C**), Turkey (**S2D**), Afg09 (**S2E**), and M18 China (**S2F**) were fitted
7 with a four-parameter non-linear regression model. Infection levels were normalized
8 relative infected cells in the absence of antibody treatment.



1
2
3
4
5
6

Supplemental Figure 3: 2-way ANOVA for IC_{50} comparisons, related to Figure 2


S3A-B QQ plots of IC_{50} values pre- (**S3A**) and post-log-transformation (**S3B**). **S3C** Residual plot of 2-way ANOVA comparison of IC_{50} values to evaluate model fit.



1
2
3
4
5
6
7
8
9
10
11

Supplemental 4: Fusion inhibition of tecVLPs (Oman) by parental mAbs and DVD-121-801 bsAb variants, related to Figure 3.

S4A-B Fusion inhibition plots (N= 4-6, n= 8-18) of linker variants (**S4A**) and 121 only variants (**S4B**) were fitted with a four-parameter non-linear regression model. The average infectivity and standard deviation for each antibody dilution is depicted. Infection levels were normalized relative to conditions with no antibody treatment. Area under the curve values were calculated and compared by one-way ANOVA with Šídák's multiple comparisons test, following tests for normality (**S4C**) and homoscedasticity (**S4D**).



1
2
3
4
5
6
7

Supplemental Figure 5: Stability studies of bsAbs variants

Aliquots of the indicated bsAbs were incubated at either 0°C or 40°C. Samples were periodically analyzed by size-exclusion chromatography (SEC). The percentage of sample in the monomeric form is graphed.